Search results
Prescriber Login. To login to your account: User Name. Password. Forgot Password?
Please select Patient Surveys and enter the information requested to begin a survey. Pharmacies: The Pharmacy Portal for Bristol Myers Squibb-administered REMS Programs can be accessed by clicking on the below button. Please enter your Username and Password to begin. If you do not have an online account, please contact your REMS Representative.
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias.
Nov 20, 2019 · Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and Celgene stockholders.
Jan 3, 2019 · Celgene shareholders will also receive one tradeable Contingent Value Right (CVR) for each share of Celgene, which will entitle the holder to receive a payment for the achievement of future regulatory milestones. The Boards of Directors of both companies have approved the combination.
Find the latest Celgene Corp (^CGQ) stock quote, history, news and other vital information to help you with your stock trading and investing.
Nov 20, 2019 · Bristol-Myers Squibb has completed its $95 billion acquisition of Celgene Corp., a deal announced at the beginning of the year. It is one of the largest acquisitions in pharmaceutical history.
Jan 4, 2019 · (Reuters) - Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, combining two of the world's largest cancer drug businesses in the biggest pharmaceutical...
Jan 3, 2019 · Drugmaker Bristol-Myers Squibb announced Thursday a $74 billion deal to buy Celgene, in one of the biggest mergers in pharmaceutical industry history.
Jan 3, 2019 · Bristol-Myers Squibb said on Thursday that it would buy Celgene, a maker of cancer-fighting drugs, in a cash-and-stock deal valued at $74 billion, the first major pharmaceutical deal of 2019.
